Welcome to our dedicated page for BECTON DICKINSON & CO SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BECTON DICKINSON & CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BECTON DICKINSON & CO's regulatory disclosures and financial reporting.
Christopher DelOrefice, EVP & Chief Financial Officer of Becton, Dickinson and Company (BDX), reported a transaction on 09/01/2025. The Form 4 shows 278 shares of BDX common stock were disposed under transaction code "F" with a reported price of $0. The explanatory note states these shares were withheld to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units. After this withholding, Mr. DelOrefice beneficially owns 21,221 shares directly. The filing was signed by Donna Kalazdy by power of attorney on 09/02/2025.
Becton, Dickinson and Company insider Richard Byrd, serving as EVP & President Interventional, reported a transaction dated 09/01/2025 involving 216 shares of BDX common stock that were disposed at a reported price of $0. The filing shows 6,736 shares owned following the transaction. The explanatory note states these 216 shares were withheld to satisfy withholding taxes related to the vesting of previously granted restricted stock units. The Form 4 was signed by a power of attorney on 09/02/2025.
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson & Co. (BDX), reported the sale of 57 shares of common stock on 08/22/2025 at a price of $197.99 per share, leaving him with 8,360 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted on August 2, 2024, indicating a prearranged, compliant insider trading plan.
Becton, Dickinson and Co. (BDX) filed a Form 144 reporting a proposed sale of 57 common shares through Morgan Stanley Smith Barney LLC. The filing states the shares were acquired as restricted stock units (RSUs) from the issuer on 08/20/2025 and the proposed approximate sale date is 08/22/2025. The filing shows an aggregate market value of $11,207.91 for the 57 shares and reports 286,627,469 shares outstanding. No securities of the issuer were reported sold by the filer in the past three months.
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson and Company (BDX), reported a non-derivative disposition of 773 shares of BDX common stock on 08/20/2025. The filing uses transaction code F, and the explanatory note states these shares were withheld to satisfy tax withholding upon vesting of previously granted restricted stock units, so the reported price is shown as $0. After the withholding, Mr. Feld beneficially owned 8,417 shares directly. The Form 4 was signed by Donna Kalazdy by power of attorney on 08/22/2025.
Becton, Dickinson and Co. is reported as having 16,178,519 shares beneficially owned by T. Rowe Price Investment Management, Inc., representing 5.6% of the outstanding common stock. The filing shows T. Rowe Price holds sole voting power over 15,106,743 shares and sole dispositive power over 16,178,519 shares, and classifies the filer as an investment adviser. The filing includes a written certification that the shares are held in the ordinary course of business and are not held to change or influence control of the company.
This Schedule 13G discloses a passive, greater-than-5%-ownership stake in BDX by a large institutional investment adviser, providing investors clarity on a significant passive holder and the exact voting and dispositive powers reported.
Becton, Dickinson and Company (BDX) has a class of debt securities, the 0.034% Notes due 2025, that the New York Stock Exchange has notified for removal from listing and registration by filing Form 25. The Exchange states it complied with rules governing delisting and the filing records that the issuer complied with the Exchange's requirements under 17 CFR 240.12d2-2(c) while the Exchange referenced compliance under 17 CFR 240.12d2-2(b).
Gregory Hayes, a director of Becton, Dickinson and Company (BDX), reported an insider purchase on 08/11/2025. The Form 4 shows an acquisition of 5,250 shares of BDX common stock at a price of $191.57, resulting in beneficial ownership of 6,046 shares held directly. The filing was executed by Donna Kalazdy by power of attorney for Mr. Hayes on 08/11/2025. The form was filed by one reporting person and lists Mr. Hayes address as c/o Becton, Dickinson and Company in Franklin Lakes, NJ.
Claire Fraser, a director of Becton, Dickinson and Company (BDX), reported a direct sale of common stock: 863 shares on 08/08/2025 at a reported price of $192.3 per share, leaving her with 23,143 shares beneficially owned directly. The Form 4 entry is coded as a sale and no derivative securities are reported in this filing.
Form 144 filed for Becton, Dickinson and Co. (BDX) indicates a proposed sale of 863 common shares, with an aggregate market value of $165,879.90, to be sold approximately on 08/08/2025 on the NYSE through Merrill Lynch. The filing shows 286,627,469 shares outstanding, so the proposed sale is a very small fraction of the company’s total shares. The securities were acquired on 01/24/2024 as a stock bonus from Claire Marie Fraser and were paid as compensation. The filer represents there are no undisclosed material adverse facts.